New York State Assembly

 
•  Summary 
 
•  Actions 
 
•  Committee Votes 
 
•  Floor Votes 
 
•  Memo 
 
•  Text 
 
•  LFIN 
 
•  Chamber Video/Transcript 

A06799 Summary:

A06799 Actions:

A06799 Committee Votes:

Committee:HEALTH   Chair:Paulin      
DATE:01/17/2024AYE/NAY:23/0  Action: Favorable refer to committee Ways and Means        
Paulin
Aye
Jensen
Aye
Dinowitz
Aye
Byrnes
Aye
Gunther
Aye
Gandolfo
Aye
Rosenthal
Aye
Mikulin
Aye
Hevesi
Excused
Blumencranz
Aye
Steck
Aye
Bendett
Aye
Braunstein
Aye
Gray
Aye
Solages
Aye
McGowan
Aye
Bichotte Hermel
Aye
Sayegh
Aye
McDonald
Aye
Reyes
Aye
Gonzalez-Rojas
Excused
Rajkumar
Aye
Forrest
Aye
Kelles
Aye
Lucas
Aye

Committee:WAYS AND MEANS   Chair:Weinstein      
DATE:05/28/2024AYE/NAY:33/0  Action: Favorable refer to committee Rules        
Weinstein
Aye
Ra
Aye
Glick
Aye
Fitzpatrick
Excused
Pretlow
Aye
Hawley
Aye
Colton
Aye
Blankenbush
Aye
Cook
Aye
Norris
Aye
Aubry
Aye
Brabenec
Aye
Benedetto
Aye
Palmesano
Aye
Weprin
Aye
Walsh
Aye
Ramos
Absent
DeStefano
Aye
Braunstein
Aye
Manktelow
Aye
McDonald
Aye
Smullen
Aye
Rozic
Aye
Dinowitz
Aye
Magnarelli
Aye
Zebrowski
Aye
Bronson
Aye
Dilan
Aye
Seawright
Aye
Hyndman
Aye
Walker
Aye
Bichotte Hermel
Aye
Simon
Aye
Cruz
Aye
Fahy
Aye

Committee:RULES   Chair:Pretlow      
DATE:05/30/2024AYE/NAY:29/0  Action: Favorable         
Heastie
Excused
Barclay
Aye
Weinstein
Aye
Hawley
Aye
Pretlow
Aye
Giglio
Aye
Cook
Aye
Blankenbush
Aye
Glick
Aye
Norris
Aye
Aubry
Aye
Ra
Aye
Dinowitz
Aye
Brabenec
Aye
Colton
Aye
Palmesano
Aye
Magnarelli
Aye
Reilly
Aye
Paulin
Aye
Peoples-Stokes
Aye
Benedetto
Aye
Lavine
Aye
Lupardo
Aye
Zebrowski
Aye
Thiele
Aye
Braunstein
Aye
Dickens
Excused
Davila
Aye
Hyndman
Aye
Rozic
Aye
Bronson
Aye

A06799 Floor Votes:

A06799 Memo:

NEW YORK STATE ASSEMBLY
MEMORANDUM IN SUPPORT OF LEGISLATION
 submitted in accordance with Assembly Rule III, Sec 1(f)



 
BILL NUMBER: A6799B
 
SPONSOR: Paulin

 
TITLE OF BILL:
 
An act to amend the public health law, in relation to establishing a
drug-induced movement disorder screening education program
 
 
PURPOSE OR GENERAL IDEA OF BILL:
 
The purpose of this legislation is to provide educational information
about the importance of screening for and recognizing symptoms of drug-
induced movement disorders, develop guidance on clinical standards for
treating drug-induced movement disorders including via telehealth, and
the elimination of bias and reduction of stigma for people living with
drug-induced movement disorders related to the treatment of mental
health conditions.
 
 
SUMMARY OF PROVISIONS:
 
Section 1 includes the legislative intent.
 
Section 2 requires the New York State Department of Health to establish
a drug-induced movement disorder screening and awareness program within
the department under the health care and wellness education and outreach
program. The program will promote education and awareness of drug-in-
duced movement disorders and screening of these disorders. It will
include the development and dissemination of educational materials for
health care providers regarding the treatment for drug-induced movement
disorders. These educational materials must be developed in coordination
with relevant health care provider groups.
 
Section 3 of this bill is the effective date of 90 days after it shall
become a law.
 
 
JUSTIFICATION:
 
Patients receiving treatment with medications for their mental health
conditions may be at risk of developing a drug-induced movement disor-
der. Drug-induced movement disorders, as discussed in the most recent
edition of the Diagnostic and Statistical Manual of Mental
Disorders(DSM-5), are of "frequent importance" when mental disorders and
other medical conditions are managed with antipsychotic medications.
These involuntary movement disorders are caused by medications that help
control dopamine, such as first- and second-generation antipsychotics
commonly prescribed to treat people living with mental illnesses like
schizophrenia, bipolar disorder, and major depression. Some drug-induced
movement disorders, such as tardivedyskinesia; are persistent, irrevers-
ible, potentially disabling neurological conditions characterized by
uncontrollable repetitive movements of the face, torso, or other parts
of the body. While untreated involuntary movements can be stigmatizing
and debilitating, the rates of undiagnosed patients living with drug-in-
duced movement disorders remains high.
 
Awareness of and periodic screenings for movement disorders are funda-
mental to the proper identification, diagnosis, and timely treatment of
drug-induced movement disorders. Recent updates to the American Psychi-
atric Association's clinical guidelines reflect the importance of
screening in people at risk of developing drug-induced movement disor-
ders, but health care and mental health providers, patients, and the
public may be unaware of these standards.
 
Under this bill, the Department of Health, through the health care and
wellness education and outreach program will provide educational infor-
mation to educate providers and the public on the importance of screen-
ing and recognizing symptoms of drug-induced movement disorders, develop
clinical guidance for treating drug-induced movement disorders including
the use of telehealth, and to provide education and outreach on the
elimination of stigma associated with drug-induced involuntary move-
ments. As part of this program, the Department should inventory existing
drug-induced movement disorder resources available, develop and maintain
educational materials and guidance for providers and the public, and
help develop training for public safety officials to recognize drug-in-
duced movement disorders.
 
Public education and information about drug-induced movement disorders
will help health professionals, public safety officials, and the commu-
nity better understand these disorders, including what causes these
types of involuntary movements and their prevalence. This can help
reduce stigma by clarifying that some abnormal movements that may be
mistaken as a public safety concern are actually uncontrollable physical
symptoms of conditions caused by medication used to treat mental
illness.
 
In addition, services provided via telehealth to patients at risk of
developing drug-induced movement disorders, such as those treated with
antipsychotic medications, should align with existing clinical standards
of care. This includes ensuring that at-risk patients are periodically
screened and assessed for developing drug-induced movement disorders.
The needs of patients living with or at risk of developing drug-induced
movement disorders encompass both mental and physical health care, and
therefore may require additional considerations when determining the
clinical appropriateness of telehealth.
 
 
PRIOR LEGISLATIVE HISTORY:
 
New bill.
 
 
FISCAL IMPLICATIONS FOR STATE AND LOCAL GOVERNMENTS:
 
Minimal as this program will be included in the already existing Depart-
ment of Health healthcare and wellness education and outreach program.
 
 
EFFECTIVE DATE:
This bill shall take effect on the 90th day after it shall have become a
law. Effective immediately, the addition, amendment and/or repeal of any
rule or regulation necessary for the implementation of this act on its
effective date are authorized to be made and completed on or before such
effective date.

A06799 Text:

 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                         6799--B
 
                               2023-2024 Regular Sessions
 
                   IN ASSEMBLY
 
                                       May 8, 2023
                                       ___________
 
        Introduced  by  M.  of  A.  PAULIN,  SAYEGH,  SEAWRIGHT -- read once and
          referred to the Committee on  Health  --  committee  discharged,  bill
          amended,  ordered reprinted as amended and recommitted to said commit-
          tee -- recommitted to the  Committee  on  Health  in  accordance  with
          Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered
          reprinted as amended and recommitted to said committee
 
        AN  ACT  to  amend  the public health law, in relation to establishing a
          drug-induced movement disorder screening education program
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section  1.  Subdivision  1 of section 207 of the public health law is
     2  amended by adding a new paragraph (h) to read as follows:
     3    (h) The department shall develop  and  conduct  a  program  concerning
     4  drug-induced  movement  disorders. Such program shall include but not be
     5  limited to, (i) educational information on the importance  of  screening
     6  for  and  identifying  symptoms  of drug-induced movement disorders; and
     7  (ii) the development and  dissemination  of  educational  materials  for
     8  healthcare  providers  regarding  treatment  for  drug-induced  movement
     9  disorders, including for services provided via telehealth.  Such  educa-
    10  tional materials disseminated to healthcare providers shall be developed
    11  and  disseminated  in  coordination  with  relevant  healthcare provider
    12  groups and shall include best practices for the treatment and  screening
    13  of  movement  disorders informed by the American Psychiatric Association
    14  and other professional society practice guidelines.  Such program  shall
    15  also  include  education  and  outreach on the elimination of stigma for
    16  people living with drug-induced movement disorders related to the treat-
    17  ment of mental health conditions.
    18    § 2. This act shall take effect on the ninetieth day  after  it  shall
    19  have become a law. Effective immediately, the addition, amendment and/or
    20  repeal  of  any  rule  or regulation necessary for the implementation of
    21  this act on its effective date are authorized to be made  and  completed
    22  on or before such effective date.
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD10964-05-4

A06799 LFIN:

 
NO LFIN

A06799 Chamber Video/Transcript: